Technical Analysis for SPPI - Spectrum Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 2.955 -0.84% -0.03
SPPI closed down 0.17 percent on Thursday, April 15, 2021, on 62 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical SPPI trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction -0.84%
NR7 Range Contraction -0.84%
NR7-2 Range Contraction -0.84%
180 Bearish Setup Bearish Swing Setup -1.01%
NR7 Range Contraction -1.01%
Stochastic Reached Oversold Weakness -1.01%
Oversold Stochastic Weakness -1.01%
Hammer Candlestick Bullish -0.34%
Lizard Bullish Bullish Day Trade Setup -0.34%
Pocket Pivot Bullish Swing Setup -0.34%
Older End-of-Day Signals for SPPI ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 2 hours ago
Down 2 % about 2 hours ago
Down 1% about 2 hours ago
Fell Below Previous Day's Low about 2 hours ago
60 Minute Opening Range Breakdown about 23 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Spectrum Pharmaceuticals, Inc. Description

Spectrum Pharmaceuticals, Inc., a biotechnology company, engages in acquiring, developing, and commercializing prescription drug products primarily in the areas of hematology and oncology. The company's oncology products include FUSILEV for patients with osteosarcoma after high-dose methotrexate therapy, and to diminish toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; and ZEVALIN, a prescribed form of cancer therapy which combines a source of radiation with an antibody. It also develops apaziquone that is under Phase III clinical trial for non-muscle invasive bladder cancer; and belinostat, which is under Phase II registrational trial for the various hematological and solid tumors. In addition, the company develops ozarelix that is under randomized phase II clinical trial in prostate cancer patients; ortataxel, which has completed Phase II studies in solid tumor patients; lucanthone, an orally administered small-molecule that has completed preclinical tests; SPI-1620, which has completed Phase I study is a peptide agonist of endothelin B receptors; RenaZorb, a second-generation lanthanum-based nanoparticle phosphate binding agent; and SPI-2012, a drug for the treatment of chemotherapy induced neutropenia. It has strategic collaborations with Allergan, Inc., Nippon Kayaku Co. Ltd., and Handok Pharmaceuticals Co. Ltd. for the development and commercialization of apaziquone; and TopoTarget A/S for the development and commercialization of belinostat. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Henderson, Nevada.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Acid Solid Tumors Lymphoma Prostate Cancer Phosphate Chemotherapy Radiation Hematology Prescription Drug Sarcoma Drug Product Bladder Cancer Drug Products Solid Tumor Treating Cancer Cancer Therapy Methotrexate Osteosarcoma Neutropenia Oncology Products Non Muscle Invasive Bladder Cancer Ozarelix Prescription Drug Product Spectrum Pharmaceuticals

Is SPPI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 5.24
52 Week Low 2.6
Average Volume 2,674,153
200-Day Moving Average 3.80
50-Day Moving Average 3.42
20-Day Moving Average 3.15
10-Day Moving Average 3.09
Average True Range 0.18
ADX 15.86
+DI 17.94
-DI 26.90
Chandelier Exit (Long, 3 ATRs ) 3.17
Chandelier Exit (Short, 3 ATRs ) 3.37
Upper Bollinger Band 3.49
Lower Bollinger Band 2.82
Percent B (%b) 0.24
BandWidth 21.21
MACD Line -0.13
MACD Signal Line -0.12
MACD Histogram -0.0091
Fundamentals Value
Market Cap 434.85 Million
Num Shares 146 Million
EPS -1.55
Price-to-Earnings (P/E) Ratio -1.93
Price-to-Sales 0.00
Price-to-Book 4.10
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.09
Resistance 3 (R3) 3.09 3.06 3.07
Resistance 2 (R2) 3.06 3.03 3.06 3.06
Resistance 1 (R1) 3.02 3.02 3.01 3.02 3.06
Pivot Point 2.99 2.99 2.98 2.99 2.99
Support 1 (S1) 2.95 2.96 2.94 2.95 2.90
Support 2 (S2) 2.92 2.95 2.92 2.90
Support 3 (S3) 2.88 2.92 2.89
Support 4 (S4) 2.88